Please login to the form below

Not currently logged in
Email:
Password:

Astellas promotes John Demaree

He becomes vice president of oncology marketing, Americas

Astellas John DemareeAstellas has appointed John Demaree as vice president of oncology marketing for its Americas operations.

In his new role, Demaree will lead the promotion of in-market products, the preparation of product launches and will collaborate with Astellas' partner organisations in the region on marketing strategy.

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

Prior to joining Astellas in 2011, Demaree served as the general manager for oncology business development and alliance management at Abbott, and also brings experience from Eli Lilly and Novartis.

Mark Reisenauer, senior vice president of the oncology business unit for Astellas Americas, said: “Astellas is committed to making a difference in the lives of cancer patients through an emphasis on innovation and R&D.

“We are confident that John's commercial experience in oncology will help us make strides in improving care for the patients we serve.”

22nd July 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Market Shaping for Better Healthcare Decisions
82% of healthcare business professionals agreed that it is important to get market shaping right to achieve future brand success....
launch engagement
Launch engagement
How the pandemic is forcing a fresh focus on the human touch and fresh thinking about engagement...
Everything you need to know about patient groups and clinical trials
Patient advocacy groups (PAGs) and pharma/biopharma/biotech and MedTech industries are all working towards the same goal: to improve health outcomes. And as PAGs are key stakeholders in the clinical trial...